Generated static export from Obsidian-friendly vault markdown
ClinPharm Vault

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

Study Snapshot

  • Program: EP262
  • Study ID(s): NCT06050928
  • Phase: Phase 1
  • Indication: Chronic Inducible Urticaria
  • Status: Completed
  • Sponsor: Escient Pharmaceuticals, Inc

Design

  • Study type: INTERVENTIONAL
  • Randomization / allocation: NA
  • Intervention model: SINGLE_GROUP
  • Masking: NONE
  • Primary purpose: TREATMENT
  • Enrollment: 33 (ACTUAL)

Population

  • Conditions: Chronic Inducible Urticaria
  • Sex: ALL
  • Age range: 18 Years to 80 Years
  • Healthy volunteers: False
  • Summary: This phase 1b trial will evaluate the effects of EP262 in subjects with Chronic Inducible Urticaria (CIndU), including symptomatic dermographism and cold urticaria.

Operational design summary

  • Arms represented in current CT.gov export: 1
  • Active dose regimens represented in current local source layer: 1
  • Total study enrollment in CT.gov: 33 (ACTUAL)
  • Per-arm sample size summary: EP262 150 mg n=33
  • Arm-size evidence source: ClinicalTrials.gov arm descriptions and summary text.

Arms

Arm Type Dose Frequency Route Description N Evidence status
EP262 150 mg EXPERIMENTAL 150 mg QD Oral Once daily 33 Directly supported by linked local publication/source text or explicit CT.gov arm-level enrollment context

Endpoints

  • Primary outcomes:
  • Safety and tolerability of EP262 (time frame: Measured from Day 1 to End of Study or Early Termination (up to 12 weeks))

Clinical Pharmacology Findings

  • PK: Not clearly summarized in the currently linked local source snippets.
  • PD: Not clearly summarized in the currently linked local source snippets.
  • Linked manuscripts: No trial-level primary publication is explicitly linked in the current registry.

Safety Findings

  • Safety detail is not strongly enriched beyond the current CT.gov/source-registry layer.

Linked Evidence

  • CT.gov page: https://clinicaltrials.gov/study/NCT06050928
  • Local CT.gov cache: raw/clinicaltrials/markdown/NCT06050928.md

Interpretation

  • Verified facts: this page reflects the current local registry and CT.gov inventory export without inferring unsupported arm sizes or endpoint results.
  • Interpretation: this trial is currently represented mainly by CT.gov and any linked sponsor-source artifacts; manual enrichment is still needed for a richer narrative page.
  • Open questions:
  • Some studies still lack exact arm-specific N in the current promoted evidence layer even when allocation schema or total enrollment is visible.
  • No explicit trial-level primary manuscript is currently linked in the registry.
  • No sponsor artifact is explicitly linked to this trial by identifier in the current registry.

Provenance

  • Source type: ClinicalTrials.gov inventory with linked sponsor/publication registry where available
  • Primary source(s):
  • NCT06050928
  • ../raw/clinicaltrials/markdown/NCT06050928.md
  • ../inventories/source_registry.json
  • Supporting source(s):
  • ../inventories/ctgov_priority_trials.json
  • Last verified: 2026-04-08
  • Verification status: Partial

Change Log

  • 2026-04-08: Generated or refreshed this study page from the v2 source registry and CT.gov inventory.